nodes	percent_of_prediction	percent_of_DWPC	metapath
Tolmetin—MPO—Carboplatin—testicular cancer	0.262	0.3	CbGbCtD
Tolmetin—MPO—Cisplatin—testicular cancer	0.224	0.256	CbGbCtD
Tolmetin—PTGS1—Ifosfamide—testicular cancer	0.134	0.153	CbGbCtD
Tolmetin—PTGS2—Cisplatin—testicular cancer	0.0773	0.0884	CbGbCtD
Tolmetin—PTGS2—Etoposide—testicular cancer	0.076	0.0868	CbGbCtD
Tolmetin—PTGS1—Etoposide—testicular cancer	0.0642	0.0733	CbGbCtD
Tolmetin—SLC22A6—Methotrexate—testicular cancer	0.0372	0.0425	CbGbCtD
Tolmetin—Lymphadenopathy—Chlorambucil—testicular cancer	0.00186	0.0164	CcSEcCtD
Tolmetin—Haemolytic anaemia—Chlorambucil—testicular cancer	0.00176	0.0155	CcSEcCtD
Tolmetin—Proteinuria—Ifosfamide—testicular cancer	0.00165	0.0145	CcSEcCtD
Tolmetin—Protein urine present—Ifosfamide—testicular cancer	0.00162	0.0143	CcSEcCtD
Tolmetin—Toxic epidermal necrolysis—Chlorambucil—testicular cancer	0.00143	0.0126	CcSEcCtD
Tolmetin—Body temperature increased—Carboplatin—testicular cancer	0.0012	0.0106	CcSEcCtD
Tolmetin—Stomatitis—Chlorambucil—testicular cancer	0.00119	0.0105	CcSEcCtD
Tolmetin—Haemolytic anaemia—Ifosfamide—testicular cancer	0.00116	0.0103	CcSEcCtD
Tolmetin—Gastrointestinal haemorrhage—Ifosfamide—testicular cancer	0.00105	0.00926	CcSEcCtD
Tolmetin—Agranulocytosis—Vinblastine—testicular cancer	0.00105	0.00923	CcSEcCtD
Tolmetin—Erythema multiforme—Chlorambucil—testicular cancer	0.00104	0.00916	CcSEcCtD
Tolmetin—Toxic epidermal necrolysis—Dactinomycin—testicular cancer	0.00103	0.0091	CcSEcCtD
Tolmetin—Haemolytic anaemia—Cisplatin—testicular cancer	0.001	0.00884	CcSEcCtD
Tolmetin—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—HPGDS—testicular cancer	0.001	0.0835	CbGpPWpGaD
Tolmetin—Cardiac failure congestive—Cisplatin—testicular cancer	0.000998	0.0088	CcSEcCtD
Tolmetin—Weight decreased—Bleomycin—testicular cancer	0.00096	0.00847	CcSEcCtD
Tolmetin—Toxic epidermal necrolysis—Ifosfamide—testicular cancer	0.000945	0.00834	CcSEcCtD
Tolmetin—Anaphylactoid reaction—Cisplatin—testicular cancer	0.000935	0.00825	CcSEcCtD
Tolmetin—Stomatitis—Bleomycin—testicular cancer	0.000922	0.00814	CcSEcCtD
Tolmetin—Cardiac failure congestive—Etoposide—testicular cancer	0.000914	0.00807	CcSEcCtD
Tolmetin—Gastrointestinal haemorrhage—Cisplatin—testicular cancer	0.000905	0.00798	CcSEcCtD
Tolmetin—Haematuria—Bleomycin—testicular cancer	0.000902	0.00796	CcSEcCtD
Tolmetin—Stomatitis—Dactinomycin—testicular cancer	0.00086	0.00759	CcSEcCtD
Tolmetin—Anaphylactoid reaction—Etoposide—testicular cancer	0.000856	0.00756	CcSEcCtD
Tolmetin—Dysuria—Ifosfamide—testicular cancer	0.000848	0.00749	CcSEcCtD
Tolmetin—Agranulocytosis—Dactinomycin—testicular cancer	0.000824	0.00727	CcSEcCtD
Tolmetin—Renal failure—Ifosfamide—testicular cancer	0.000795	0.00702	CcSEcCtD
Tolmetin—PTGS2—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—HPGDS—testicular cancer	0.000794	0.0663	CbGpPWpGaD
Tolmetin—Hepatitis—Dactinomycin—testicular cancer	0.000792	0.00699	CcSEcCtD
Tolmetin—Stomatitis—Ifosfamide—testicular cancer	0.000788	0.00696	CcSEcCtD
Tolmetin—Proteinuria—Methotrexate—testicular cancer	0.000778	0.00687	CcSEcCtD
Tolmetin—Haematuria—Ifosfamide—testicular cancer	0.000771	0.00681	CcSEcCtD
Tolmetin—Protein urine present—Methotrexate—testicular cancer	0.000768	0.00677	CcSEcCtD
Tolmetin—Thrombocytopenia—Chlorambucil—testicular cancer	0.000763	0.00674	CcSEcCtD
Tolmetin—Agranulocytosis—Ifosfamide—testicular cancer	0.000755	0.00666	CcSEcCtD
Tolmetin—Abdominal discomfort—Cisplatin—testicular cancer	0.00075	0.00662	CcSEcCtD
Tolmetin—Erythema multiforme—Dactinomycin—testicular cancer	0.000749	0.00661	CcSEcCtD
Tolmetin—Toxic epidermal necrolysis—Etoposide—testicular cancer	0.000746	0.00659	CcSEcCtD
Tolmetin—Glossitis—Methotrexate—testicular cancer	0.000742	0.00655	CcSEcCtD
Tolmetin—Hepatitis—Ifosfamide—testicular cancer	0.000726	0.00641	CcSEcCtD
Tolmetin—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A6—testicular cancer	0.000723	0.0604	CbGpPWpGaD
Tolmetin—Thrombocytopenia—Vinblastine—testicular cancer	0.0007	0.00617	CcSEcCtD
Tolmetin—Visual impairment—Ifosfamide—testicular cancer	0.0007	0.00617	CcSEcCtD
Tolmetin—Glossitis—Epirubicin—testicular cancer	0.000694	0.00613	CcSEcCtD
Tolmetin—Erythema multiforme—Ifosfamide—testicular cancer	0.000686	0.00606	CcSEcCtD
Tolmetin—Dyspepsia—Chlorambucil—testicular cancer	0.000686	0.00606	CcSEcCtD
Tolmetin—Renal failure—Cisplatin—testicular cancer	0.000685	0.00605	CcSEcCtD
Tolmetin—Stomatitis—Cisplatin—testicular cancer	0.00068	0.006	CcSEcCtD
Tolmetin—Tinnitus—Ifosfamide—testicular cancer	0.000677	0.00597	CcSEcCtD
Tolmetin—CXCL8—Syndecan-3-mediated signaling events—FGFR3—testicular cancer	0.000654	0.0546	CbGpPWpGaD
Tolmetin—Glossitis—Doxorubicin—testicular cancer	0.000643	0.00567	CcSEcCtD
Tolmetin—Gastrointestinal pain—Chlorambucil—testicular cancer	0.000638	0.00563	CcSEcCtD
Tolmetin—Chest pain—Bleomycin—testicular cancer	0.00063	0.00556	CcSEcCtD
Tolmetin—Renal failure—Etoposide—testicular cancer	0.000628	0.00554	CcSEcCtD
Tolmetin—Stomatitis—Etoposide—testicular cancer	0.000623	0.00549	CcSEcCtD
Tolmetin—Urticaria—Chlorambucil—testicular cancer	0.000619	0.00547	CcSEcCtD
Tolmetin—Abdominal pain—Chlorambucil—testicular cancer	0.000616	0.00544	CcSEcCtD
Tolmetin—Body temperature increased—Chlorambucil—testicular cancer	0.000616	0.00544	CcSEcCtD
Tolmetin—Constipation—Vinblastine—testicular cancer	0.000611	0.00539	CcSEcCtD
Tolmetin—MPO—C-MYB transcription factor network—MAD1L1—testicular cancer	0.000611	0.051	CbGpPWpGaD
Tolmetin—Blood urea increased—Epirubicin—testicular cancer	0.000604	0.00533	CcSEcCtD
Tolmetin—Oedema—Bleomycin—testicular cancer	0.000603	0.00533	CcSEcCtD
Tolmetin—Anaphylactic shock—Bleomycin—testicular cancer	0.000603	0.00533	CcSEcCtD
Tolmetin—Visual impairment—Cisplatin—testicular cancer	0.000603	0.00532	CcSEcCtD
Tolmetin—Agranulocytosis—Etoposide—testicular cancer	0.000596	0.00526	CcSEcCtD
Tolmetin—Thrombocytopenia—Bleomycin—testicular cancer	0.000591	0.00522	CcSEcCtD
Tolmetin—Gastrointestinal pain—Vinblastine—testicular cancer	0.000584	0.00516	CcSEcCtD
Tolmetin—Tinnitus—Cisplatin—testicular cancer	0.000584	0.00515	CcSEcCtD
Tolmetin—Lymphadenopathy—Methotrexate—testicular cancer	0.000582	0.00514	CcSEcCtD
Tolmetin—Abdominal pain—Vinblastine—testicular cancer	0.000565	0.00499	CcSEcCtD
Tolmetin—Oedema—Dactinomycin—testicular cancer	0.000563	0.00497	CcSEcCtD
Tolmetin—Asthenia—Chlorambucil—testicular cancer	0.000559	0.00494	CcSEcCtD
Tolmetin—Blood urea increased—Doxorubicin—testicular cancer	0.000559	0.00493	CcSEcCtD
Tolmetin—Thrombocytopenia—Dactinomycin—testicular cancer	0.000551	0.00486	CcSEcCtD
Tolmetin—Lymphadenopathy—Epirubicin—testicular cancer	0.000545	0.00481	CcSEcCtD
Tolmetin—Erythema multiforme—Etoposide—testicular cancer	0.000542	0.00478	CcSEcCtD
Tolmetin—Chest pain—Ifosfamide—testicular cancer	0.000538	0.00475	CcSEcCtD
Tolmetin—Flatulence—Cisplatin—testicular cancer	0.000537	0.00474	CcSEcCtD
Tolmetin—Diarrhoea—Chlorambucil—testicular cancer	0.000533	0.00471	CcSEcCtD
Tolmetin—Visual disturbance—Methotrexate—testicular cancer	0.000524	0.00462	CcSEcCtD
Tolmetin—Vascular purpura—Epirubicin—testicular cancer	0.000519	0.00458	CcSEcCtD
Tolmetin—Anaphylactic shock—Ifosfamide—testicular cancer	0.000516	0.00455	CcSEcCtD
Tolmetin—Oedema—Ifosfamide—testicular cancer	0.000516	0.00455	CcSEcCtD
Tolmetin—CXCL8—Peptide ligand-binding receptors—INSL3—testicular cancer	0.000513	0.0429	CbGpPWpGaD
Tolmetin—Anaphylactoid reaction—Methotrexate—testicular cancer	0.000513	0.00453	CcSEcCtD
Tolmetin—Asthenia—Vinblastine—testicular cancer	0.000513	0.00452	CcSEcCtD
Tolmetin—Cardiac failure congestive—Epirubicin—testicular cancer	0.000512	0.00452	CcSEcCtD
Tolmetin—Thrombocytopenia—Ifosfamide—testicular cancer	0.000505	0.00446	CcSEcCtD
Tolmetin—Lymphadenopathy—Doxorubicin—testicular cancer	0.000504	0.00445	CcSEcCtD
Tolmetin—Vomiting—Chlorambucil—testicular cancer	0.000496	0.00438	CcSEcCtD
Tolmetin—Diarrhoea—Vinblastine—testicular cancer	0.000489	0.00431	CcSEcCtD
Tolmetin—Purpura—Epirubicin—testicular cancer	0.000482	0.00425	CcSEcCtD
Tolmetin—Vascular purpura—Doxorubicin—testicular cancer	0.000481	0.00424	CcSEcCtD
Tolmetin—Anaphylactoid reaction—Epirubicin—testicular cancer	0.00048	0.00424	CcSEcCtD
Tolmetin—Urticaria—Bleomycin—testicular cancer	0.000479	0.00423	CcSEcCtD
Tolmetin—CXCL8—Bladder Cancer—FGFR3—testicular cancer	0.000479	0.04	CbGpPWpGaD
Tolmetin—Body temperature increased—Bleomycin—testicular cancer	0.000477	0.00421	CcSEcCtD
Tolmetin—Cardiac failure congestive—Doxorubicin—testicular cancer	0.000474	0.00418	CcSEcCtD
Tolmetin—Dizziness—Vinblastine—testicular cancer	0.000472	0.00417	CcSEcCtD
Tolmetin—Gastrointestinal haemorrhage—Epirubicin—testicular cancer	0.000465	0.0041	CcSEcCtD
Tolmetin—Nausea—Chlorambucil—testicular cancer	0.000463	0.00409	CcSEcCtD
Tolmetin—Gastrointestinal pain—Dactinomycin—testicular cancer	0.00046	0.00406	CcSEcCtD
Tolmetin—Somnolence—Ifosfamide—testicular cancer	0.000458	0.00405	CcSEcCtD
Tolmetin—Vomiting—Vinblastine—testicular cancer	0.000454	0.00401	CcSEcCtD
Tolmetin—Headache—Vinblastine—testicular cancer	0.000448	0.00395	CcSEcCtD
Tolmetin—Toxic epidermal necrolysis—Methotrexate—testicular cancer	0.000447	0.00395	CcSEcCtD
Tolmetin—Purpura—Doxorubicin—testicular cancer	0.000446	0.00394	CcSEcCtD
Tolmetin—Body temperature increased—Dactinomycin—testicular cancer	0.000445	0.00393	CcSEcCtD
Tolmetin—Abdominal pain—Dactinomycin—testicular cancer	0.000445	0.00393	CcSEcCtD
Tolmetin—Oedema—Cisplatin—testicular cancer	0.000445	0.00392	CcSEcCtD
Tolmetin—Anaphylactic shock—Cisplatin—testicular cancer	0.000445	0.00392	CcSEcCtD
Tolmetin—Anaphylactoid reaction—Doxorubicin—testicular cancer	0.000444	0.00392	CcSEcCtD
Tolmetin—Constipation—Ifosfamide—testicular cancer	0.000441	0.00389	CcSEcCtD
Tolmetin—Thrombocytopenia—Cisplatin—testicular cancer	0.000435	0.00384	CcSEcCtD
Tolmetin—Asthenia—Bleomycin—testicular cancer	0.000433	0.00382	CcSEcCtD
Tolmetin—Gastrointestinal haemorrhage—Doxorubicin—testicular cancer	0.00043	0.00379	CcSEcCtD
Tolmetin—MPO—C-MYB transcription factor network—H2AFZ—testicular cancer	0.000426	0.0355	CbGpPWpGaD
Tolmetin—CXCL8—Syndecan-2-mediated signaling events—FGFR3—testicular cancer	0.000425	0.0355	CbGpPWpGaD
Tolmetin—Chest pain—Etoposide—testicular cancer	0.000425	0.00375	CcSEcCtD
Tolmetin—Nausea—Vinblastine—testicular cancer	0.000424	0.00375	CcSEcCtD
Tolmetin—Gastrointestinal pain—Ifosfamide—testicular cancer	0.000422	0.00372	CcSEcCtD
Tolmetin—Toxic epidermal necrolysis—Epirubicin—testicular cancer	0.000418	0.00369	CcSEcCtD
Tolmetin—Abdominal discomfort—Methotrexate—testicular cancer	0.000411	0.00363	CcSEcCtD
Tolmetin—Gastritis—Epirubicin—testicular cancer	0.000411	0.00363	CcSEcCtD
Tolmetin—Urticaria—Ifosfamide—testicular cancer	0.00041	0.00362	CcSEcCtD
Tolmetin—Body temperature increased—Ifosfamide—testicular cancer	0.000408	0.0036	CcSEcCtD
Tolmetin—Abdominal pain—Ifosfamide—testicular cancer	0.000408	0.0036	CcSEcCtD
Tolmetin—Anaphylactic shock—Etoposide—testicular cancer	0.000407	0.0036	CcSEcCtD
Tolmetin—Asthenia—Dactinomycin—testicular cancer	0.000404	0.00356	CcSEcCtD
Tolmetin—Dysuria—Methotrexate—testicular cancer	0.000401	0.00354	CcSEcCtD
Tolmetin—Thrombocytopenia—Etoposide—testicular cancer	0.000399	0.00352	CcSEcCtD
Tolmetin—MPO—C-MYB transcription factor network—KITLG—testicular cancer	0.000392	0.0327	CbGpPWpGaD
Tolmetin—Toxic epidermal necrolysis—Doxorubicin—testicular cancer	0.000387	0.00342	CcSEcCtD
Tolmetin—Diarrhoea—Dactinomycin—testicular cancer	0.000385	0.0034	CcSEcCtD
Tolmetin—Vomiting—Bleomycin—testicular cancer	0.000384	0.00339	CcSEcCtD
Tolmetin—Drowsiness—Methotrexate—testicular cancer	0.000383	0.00338	CcSEcCtD
Tolmetin—Gastritis—Doxorubicin—testicular cancer	0.00038	0.00336	CcSEcCtD
Tolmetin—Renal failure—Methotrexate—testicular cancer	0.000376	0.00332	CcSEcCtD
Tolmetin—Dysuria—Epirubicin—testicular cancer	0.000375	0.00331	CcSEcCtD
Tolmetin—Stomatitis—Methotrexate—testicular cancer	0.000373	0.00329	CcSEcCtD
Tolmetin—Asthenia—Ifosfamide—testicular cancer	0.00037	0.00327	CcSEcCtD
Tolmetin—Weight increased—Epirubicin—testicular cancer	0.000365	0.00323	CcSEcCtD
Tolmetin—Haematuria—Methotrexate—testicular cancer	0.000365	0.00322	CcSEcCtD
Tolmetin—Weight decreased—Epirubicin—testicular cancer	0.000363	0.00321	CcSEcCtD
Tolmetin—Somnolence—Etoposide—testicular cancer	0.000362	0.0032	CcSEcCtD
Tolmetin—PTGS1—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000361	0.0301	CbGpPWpGaD
Tolmetin—Epistaxis—Methotrexate—testicular cancer	0.000361	0.00318	CcSEcCtD
Tolmetin—Nausea—Bleomycin—testicular cancer	0.000358	0.00316	CcSEcCtD
Tolmetin—Drowsiness—Epirubicin—testicular cancer	0.000358	0.00316	CcSEcCtD
Tolmetin—Vomiting—Dactinomycin—testicular cancer	0.000358	0.00316	CcSEcCtD
Tolmetin—Agranulocytosis—Methotrexate—testicular cancer	0.000357	0.00315	CcSEcCtD
Tolmetin—Diarrhoea—Ifosfamide—testicular cancer	0.000353	0.00311	CcSEcCtD
Tolmetin—Renal failure—Epirubicin—testicular cancer	0.000352	0.00311	CcSEcCtD
Tolmetin—Body temperature increased—Cisplatin—testicular cancer	0.000351	0.0031	CcSEcCtD
Tolmetin—Stomatitis—Epirubicin—testicular cancer	0.000349	0.00308	CcSEcCtD
Tolmetin—Constipation—Etoposide—testicular cancer	0.000348	0.00307	CcSEcCtD
Tolmetin—Urinary tract infection—Epirubicin—testicular cancer	0.000348	0.00307	CcSEcCtD
Tolmetin—Dysuria—Doxorubicin—testicular cancer	0.000347	0.00307	CcSEcCtD
Tolmetin—CXCL8—Syndecan-2-mediated signaling events—MMP2—testicular cancer	0.000346	0.0289	CbGpPWpGaD
Tolmetin—CXCL8—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000344	0.0288	CbGpPWpGaD
Tolmetin—Hepatitis—Methotrexate—testicular cancer	0.000343	0.00303	CcSEcCtD
Tolmetin—Haematuria—Epirubicin—testicular cancer	0.000341	0.00301	CcSEcCtD
Tolmetin—Dizziness—Ifosfamide—testicular cancer	0.000341	0.00301	CcSEcCtD
Tolmetin—CXCL8—Validated transcriptional targets of AP1 family members Fra1 and Fra2—MMP2—testicular cancer	0.000338	0.0283	CbGpPWpGaD
Tolmetin—Weight increased—Doxorubicin—testicular cancer	0.000338	0.00298	CcSEcCtD
Tolmetin—Epistaxis—Epirubicin—testicular cancer	0.000338	0.00298	CcSEcCtD
Tolmetin—Weight decreased—Doxorubicin—testicular cancer	0.000336	0.00297	CcSEcCtD
Tolmetin—Nausea—Dactinomycin—testicular cancer	0.000334	0.00295	CcSEcCtD
Tolmetin—Agranulocytosis—Epirubicin—testicular cancer	0.000334	0.00295	CcSEcCtD
Tolmetin—Gastrointestinal pain—Etoposide—testicular cancer	0.000333	0.00294	CcSEcCtD
Tolmetin—Drowsiness—Doxorubicin—testicular cancer	0.000331	0.00292	CcSEcCtD
Tolmetin—Visual impairment—Methotrexate—testicular cancer	0.000331	0.00292	CcSEcCtD
Tolmetin—SLC22A6—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	0.000329	0.0274	CbGpPWpGaD
Tolmetin—Vomiting—Ifosfamide—testicular cancer	0.000328	0.00289	CcSEcCtD
Tolmetin—Renal failure—Doxorubicin—testicular cancer	0.000326	0.00287	CcSEcCtD
Tolmetin—Erythema multiforme—Methotrexate—testicular cancer	0.000325	0.00287	CcSEcCtD
Tolmetin—Urticaria—Etoposide—testicular cancer	0.000324	0.00286	CcSEcCtD
Tolmetin—Stomatitis—Doxorubicin—testicular cancer	0.000323	0.00285	CcSEcCtD
Tolmetin—Abdominal pain—Etoposide—testicular cancer	0.000322	0.00284	CcSEcCtD
Tolmetin—Body temperature increased—Etoposide—testicular cancer	0.000322	0.00284	CcSEcCtD
Tolmetin—Urinary tract infection—Doxorubicin—testicular cancer	0.000322	0.00284	CcSEcCtD
Tolmetin—Hepatitis—Epirubicin—testicular cancer	0.000321	0.00284	CcSEcCtD
Tolmetin—Tinnitus—Methotrexate—testicular cancer	0.00032	0.00283	CcSEcCtD
Tolmetin—Asthenia—Cisplatin—testicular cancer	0.000319	0.00282	CcSEcCtD
Tolmetin—Haematuria—Doxorubicin—testicular cancer	0.000316	0.00279	CcSEcCtD
Tolmetin—Epistaxis—Doxorubicin—testicular cancer	0.000312	0.00276	CcSEcCtD
Tolmetin—Visual impairment—Epirubicin—testicular cancer	0.00031	0.00273	CcSEcCtD
Tolmetin—Agranulocytosis—Doxorubicin—testicular cancer	0.000309	0.00273	CcSEcCtD
Tolmetin—PTGS2—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	0.000306	0.0256	CbGpPWpGaD
Tolmetin—Nausea—Ifosfamide—testicular cancer	0.000306	0.0027	CcSEcCtD
Tolmetin—Diarrhoea—Cisplatin—testicular cancer	0.000304	0.00269	CcSEcCtD
Tolmetin—Erythema multiforme—Epirubicin—testicular cancer	0.000304	0.00268	CcSEcCtD
Tolmetin—Tinnitus—Epirubicin—testicular cancer	0.0003	0.00264	CcSEcCtD
Tolmetin—Hepatitis—Doxorubicin—testicular cancer	0.000297	0.00262	CcSEcCtD
Tolmetin—Asthenia—Etoposide—testicular cancer	0.000292	0.00258	CcSEcCtD
Tolmetin—PTGS2—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000287	0.0239	CbGpPWpGaD
Tolmetin—Visual impairment—Doxorubicin—testicular cancer	0.000287	0.00253	CcSEcCtD
Tolmetin—Vomiting—Cisplatin—testicular cancer	0.000283	0.0025	CcSEcCtD
Tolmetin—Erythema multiforme—Doxorubicin—testicular cancer	0.000281	0.00248	CcSEcCtD
Tolmetin—Diarrhoea—Etoposide—testicular cancer	0.000279	0.00246	CcSEcCtD
Tolmetin—Tinnitus—Doxorubicin—testicular cancer	0.000277	0.00245	CcSEcCtD
Tolmetin—Flatulence—Epirubicin—testicular cancer	0.000276	0.00243	CcSEcCtD
Tolmetin—Dizziness—Etoposide—testicular cancer	0.000269	0.00238	CcSEcCtD
Tolmetin—MPO—C-MYB transcription factor network—KIT—testicular cancer	0.000267	0.0223	CbGpPWpGaD
Tolmetin—CXCL8—Senescence-Associated Secretory Phenotype (SASP)—H2AFZ—testicular cancer	0.000264	0.0221	CbGpPWpGaD
Tolmetin—Nausea—Cisplatin—testicular cancer	0.000264	0.00233	CcSEcCtD
Tolmetin—CXCL8—GPCR ligand binding—INSL3—testicular cancer	0.000262	0.0219	CbGpPWpGaD
Tolmetin—Vomiting—Etoposide—testicular cancer	0.000259	0.00229	CcSEcCtD
Tolmetin—Headache—Etoposide—testicular cancer	0.000255	0.00225	CcSEcCtD
Tolmetin—Flatulence—Doxorubicin—testicular cancer	0.000255	0.00225	CcSEcCtD
Tolmetin—Chest pain—Methotrexate—testicular cancer	0.000255	0.00225	CcSEcCtD
Tolmetin—Anaphylactic shock—Methotrexate—testicular cancer	0.000244	0.00215	CcSEcCtD
Tolmetin—Nausea—Etoposide—testicular cancer	0.000242	0.00214	CcSEcCtD
Tolmetin—Thrombocytopenia—Methotrexate—testicular cancer	0.000239	0.00211	CcSEcCtD
Tolmetin—Chest pain—Epirubicin—testicular cancer	0.000238	0.0021	CcSEcCtD
Tolmetin—CXCL8—ATF-2 transcription factor network—MMP2—testicular cancer	0.000233	0.0195	CbGpPWpGaD
Tolmetin—Anaphylactic shock—Epirubicin—testicular cancer	0.000228	0.00202	CcSEcCtD
Tolmetin—Oedema—Epirubicin—testicular cancer	0.000228	0.00202	CcSEcCtD
Tolmetin—Thrombocytopenia—Epirubicin—testicular cancer	0.000224	0.00197	CcSEcCtD
Tolmetin—Chest pain—Doxorubicin—testicular cancer	0.00022	0.00195	CcSEcCtD
Tolmetin—CXCL8—LPA receptor mediated events—MMP2—testicular cancer	0.000218	0.0182	CbGpPWpGaD
Tolmetin—Somnolence—Methotrexate—testicular cancer	0.000217	0.00191	CcSEcCtD
Tolmetin—Dyspepsia—Methotrexate—testicular cancer	0.000215	0.0019	CcSEcCtD
Tolmetin—Oedema—Doxorubicin—testicular cancer	0.000211	0.00186	CcSEcCtD
Tolmetin—Anaphylactic shock—Doxorubicin—testicular cancer	0.000211	0.00186	CcSEcCtD
Tolmetin—Thrombocytopenia—Doxorubicin—testicular cancer	0.000207	0.00183	CcSEcCtD
Tolmetin—Somnolence—Epirubicin—testicular cancer	0.000203	0.00179	CcSEcCtD
Tolmetin—Dyspepsia—Epirubicin—testicular cancer	0.000201	0.00177	CcSEcCtD
Tolmetin—Gastrointestinal pain—Methotrexate—testicular cancer	0.0002	0.00176	CcSEcCtD
Tolmetin—PTGS2—C-MYB transcription factor network—MAD1L1—testicular cancer	0.000198	0.0166	CbGpPWpGaD
Tolmetin—Constipation—Epirubicin—testicular cancer	0.000195	0.00172	CcSEcCtD
Tolmetin—Urticaria—Methotrexate—testicular cancer	0.000194	0.00171	CcSEcCtD
Tolmetin—Body temperature increased—Methotrexate—testicular cancer	0.000193	0.0017	CcSEcCtD
Tolmetin—Abdominal pain—Methotrexate—testicular cancer	0.000193	0.0017	CcSEcCtD
Tolmetin—Somnolence—Doxorubicin—testicular cancer	0.000188	0.00166	CcSEcCtD
Tolmetin—Gastrointestinal pain—Epirubicin—testicular cancer	0.000187	0.00165	CcSEcCtD
Tolmetin—Dyspepsia—Doxorubicin—testicular cancer	0.000186	0.00164	CcSEcCtD
Tolmetin—CXCL8—Regulation of nuclear beta catenin signaling and target gene transcription—MMP2—testicular cancer	0.000183	0.0152	CbGpPWpGaD
Tolmetin—Urticaria—Epirubicin—testicular cancer	0.000181	0.0016	CcSEcCtD
Tolmetin—Constipation—Doxorubicin—testicular cancer	0.000181	0.00159	CcSEcCtD
Tolmetin—Abdominal pain—Epirubicin—testicular cancer	0.000181	0.00159	CcSEcCtD
Tolmetin—Body temperature increased—Epirubicin—testicular cancer	0.000181	0.00159	CcSEcCtD
Tolmetin—Asthenia—Methotrexate—testicular cancer	0.000175	0.00155	CcSEcCtD
Tolmetin—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000173	0.00152	CcSEcCtD
Tolmetin—Urticaria—Doxorubicin—testicular cancer	0.000168	0.00148	CcSEcCtD
Tolmetin—CXCL8—Cellular Senescence—H2AFZ—testicular cancer	0.000167	0.014	CbGpPWpGaD
Tolmetin—SLC22A6—Transmembrane transport of small molecules—SLC2A6—testicular cancer	0.000167	0.0139	CbGpPWpGaD
Tolmetin—Abdominal pain—Doxorubicin—testicular cancer	0.000167	0.00147	CcSEcCtD
Tolmetin—Body temperature increased—Doxorubicin—testicular cancer	0.000167	0.00147	CcSEcCtD
Tolmetin—Diarrhoea—Methotrexate—testicular cancer	0.000167	0.00147	CcSEcCtD
Tolmetin—Asthenia—Epirubicin—testicular cancer	0.000164	0.00145	CcSEcCtD
Tolmetin—Dizziness—Methotrexate—testicular cancer	0.000161	0.00142	CcSEcCtD
Tolmetin—Diarrhoea—Epirubicin—testicular cancer	0.000156	0.00138	CcSEcCtD
Tolmetin—Vomiting—Methotrexate—testicular cancer	0.000155	0.00137	CcSEcCtD
Tolmetin—Headache—Methotrexate—testicular cancer	0.000153	0.00135	CcSEcCtD
Tolmetin—Asthenia—Doxorubicin—testicular cancer	0.000152	0.00134	CcSEcCtD
Tolmetin—Dizziness—Epirubicin—testicular cancer	0.000151	0.00133	CcSEcCtD
Tolmetin—CXCL8—GPCR downstream signaling—INSL3—testicular cancer	0.000148	0.0124	CbGpPWpGaD
Tolmetin—Vomiting—Epirubicin—testicular cancer	0.000145	0.00128	CcSEcCtD
Tolmetin—Nausea—Methotrexate—testicular cancer	0.000145	0.00128	CcSEcCtD
Tolmetin—Diarrhoea—Doxorubicin—testicular cancer	0.000145	0.00128	CcSEcCtD
Tolmetin—Headache—Epirubicin—testicular cancer	0.000143	0.00126	CcSEcCtD
Tolmetin—Dizziness—Doxorubicin—testicular cancer	0.00014	0.00123	CcSEcCtD
Tolmetin—PTGS2—C-MYB transcription factor network—H2AFZ—testicular cancer	0.000138	0.0115	CbGpPWpGaD
Tolmetin—Nausea—Epirubicin—testicular cancer	0.000136	0.0012	CcSEcCtD
Tolmetin—CXCL8—Signaling by GPCR—INSL3—testicular cancer	0.000135	0.0112	CbGpPWpGaD
Tolmetin—PTGS1—Biological oxidations—HPGDS—testicular cancer	0.000134	0.0112	CbGpPWpGaD
Tolmetin—Vomiting—Doxorubicin—testicular cancer	0.000134	0.00119	CcSEcCtD
Tolmetin—Headache—Doxorubicin—testicular cancer	0.000132	0.00117	CcSEcCtD
Tolmetin—PTGS2—C-MYB transcription factor network—KITLG—testicular cancer	0.000127	0.0106	CbGpPWpGaD
Tolmetin—CXCL8—Cellular responses to stress—H2AFZ—testicular cancer	0.000126	0.0105	CbGpPWpGaD
Tolmetin—Nausea—Doxorubicin—testicular cancer	0.000125	0.00111	CcSEcCtD
Tolmetin—TDO2—Metabolism—HPGDS—testicular cancer	0.000107	0.00893	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	9.81e-05	0.00819	CbGpPWpGaD
Tolmetin—PTGS2—C-MYB transcription factor network—KIT—testicular cancer	8.68e-05	0.00725	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—INSL3—testicular cancer	7.95e-05	0.00664	CbGpPWpGaD
Tolmetin—TDO2—Metabolism—STK11—testicular cancer	7.77e-05	0.00649	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	7.13e-05	0.00595	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	5.16e-05	0.00431	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	4.1e-05	0.00342	CbGpPWpGaD
Tolmetin—CXCL8—Metabolism of proteins—MMP2—testicular cancer	3.28e-05	0.00274	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—H2AFZ—testicular cancer	2.54e-05	0.00213	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—STK11—testicular cancer	2.53e-05	0.00211	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—KITLG—testicular cancer	2.34e-05	0.00195	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—HPGDS—testicular cancer	2.3e-05	0.00192	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—HPGDS—testicular cancer	1.82e-05	0.00152	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—FGFR3—testicular cancer	1.74e-05	0.00145	CbGpPWpGaD
Tolmetin—PTGS1—Metabolism—STK11—testicular cancer	1.67e-05	0.00139	CbGpPWpGaD
Tolmetin—CXCL8—Signaling Pathways—KIT—testicular cancer	1.6e-05	0.00133	CbGpPWpGaD
Tolmetin—PTGS2—Disease—H2AFZ—testicular cancer	1.59e-05	0.00133	CbGpPWpGaD
Tolmetin—PTGS2—Disease—KITLG—testicular cancer	1.46e-05	0.00122	CbGpPWpGaD
Tolmetin—PTGS2—Metabolism—STK11—testicular cancer	1.33e-05	0.00111	CbGpPWpGaD
Tolmetin—PTGS2—Disease—FGFR3—testicular cancer	1.09e-05	0.000909	CbGpPWpGaD
Tolmetin—PTGS2—Disease—KIT—testicular cancer	9.99e-06	0.000834	CbGpPWpGaD
